Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% vs PIRFENIDONE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Aminophylline is a complex of theophylline and ethylenediamine, acting as a phosphodiesterase inhibitor, increasing intracellular c AMP levels; nonselective adenosine receptor antagonist; enhances cardiac inotropy, bronchodilation, and CNS stimulation.
Pirfenidone is a pyridone derivative that inhibits TGF-β1-mediated collagen synthesis, reduces fibroblast proliferation, and downregulates the production of pro-inflammatory cytokines (e.g., TNF-α, IL-1β) and growth factors. Its exact mechanism in idiopathic pulmonary fibrosis (IPF) is not fully elucidated, but it is thought to exert antifibrotic and anti-inflammatory effects.
Treatment of acute bronchospasm in asthma and COPD,Reversal of dipyridamole-induced adverse effects during stress testing,Apnea of prematurity (off-label),Status asthmaticus (off-label)
Idiopathic pulmonary fibrosis (IPF)
Loading dose: 5-6 mg/kg IV over 20-30 minutes, then continuous infusion: 0.5-0.7 mg/kg/hour IV.
801 mg orally three times daily with food, total daily dose 2403 mg. Starting dose: 267 mg three times daily for first 7 days, then 534 mg three times daily for 7 days, then maintenance 801 mg three times daily.
Terminal elimination half-life is 6-12 hours in adults, 1-5 hours in children (due to faster clearance), 20-30 hours in premature neonates, and 10-15 hours in patients with hepatic cirrhosis or heart failure. Clinical context: dosing interval adjustment required based on half-life; prolonged half-life in hepatic impairment or cardiac decompensation increases risk of toxicity.
Terminal elimination half-life: ~2.5 hours (range 1.5–3.5 h); clinical context: no accumulation with twice-daily dosing; steady-state reached within 2–3 days.
Hepatic via cytochrome P450 enzymes (CYP1A2, CYP3A4, CYP2E1); saturable kinetics; extensive first-pass metabolism.
Primarily hepatic metabolism via CYP1A2, with minor contributions from other CYP enzymes (CYP2C9, CYP2C19, CYP2D6, CYP2E1).
Renal excretion of unchanged theophylline (10-20%) and metabolites (80-90%). In neonates, renal excretion of unchanged drug is higher (up to 50%). Biliary/fecal excretion is negligible.
Renal: ~80% (mostly as unchanged drug and metabolites); fecal: ~20%.
Approximately 40% bound to plasma proteins, mainly albumin. In neonates, preterm infants, and patients with hepatic cirrhosis, protein binding is reduced (free fraction increases). Binding is also saturable at high theophylline concentrations.
~60–70% bound to plasma proteins (primarily albumin).
Volume of distribution is approximately 0.45 L/kg (range 0.3-0.7 L/kg) in adults. In neonates, Vd is larger (~0.6-0.8 L/kg). Clinical meaning: Vd indicates extensive distribution into body water; loading doses are calculated using Vd (e.g., 1 mg/kg raises serum concentration by ~2 mcg/m L).
Vd: ~1 L/kg (range 0.8–1.2 L/kg); clinical meaning: extensive tissue distribution.
Oral immediate-release: 100% (well absorbed). Rectal: 80-100% (absorption may be erratic). IV: 100%. No significant first-pass metabolism.
Oral: ~80–85% (high bioavailability with minimal first-pass metabolism).
No specific dose adjustment required for GFR >10 m L/min. For GFR <10 m L/min, reduce infusion rate by 50%.
Contraindicated in GFR < 30 m L/min. For GFR 30-50 m L/min: reduce to 267 mg three times daily; monitor for adverse effects. No adjustment for GFR > 50 m L/min.
Child-Pugh Class A: reduce dose by 25%; Class B: reduce dose by 50%; Class C: reduce dose by 75%.
Child-Pugh Class A: no adjustment. Child-Pugh Class B: contraindicated (insufficient data). Child-Pugh Class C: contraindicated.
Loading dose: 5-6 mg/kg IV over 20-30 minutes; continuous infusion: 0.5-0.7 mg/kg/hour (age-dependent, with lower doses for younger children).
Not approved for pediatric patients; safety and efficacy not established. No weight-based dosing guidelines available.
Elderly patients may have reduced clearance; consider starting at the lower end of dosing range (e.g., 0.3-0.5 mg/kg/hour) and titrate based on serum levels.
No specific dose adjustment required; use caution due to potential increased sensitivity and higher incidence of renal impairment. Monitor renal function and gastrointestinal tolerability.
Theophylline toxicity is dose-related and can be fatal; monitor serum theophylline levels closely; use with caution in patients with risk factors for reduced clearance (e.g., hepatic impairment, heart failure, elderly).
No FDA black box warnings.
Narrow therapeutic index; severe toxicity can occur at levels >20 mcg/m L,Seizures and arrhythmias may occur without preceding symptoms,Variable clearance due to drug interactions, disease states, age, and smoking,Use with caution in peptic ulcer disease, seizure disorders, hyperthyroidism, and cardiac disease
Hepatotoxicity: Elevations in liver enzymes and potential drug-induced liver injury; monitor LFTs regularly.,Photosensitivity: Avoid sun exposure; use broad-spectrum sunscreen.,Gastrointestinal effects: Nausea, diarrhea, dyspepsia; may require dose adjustment.,Drug interactions: Coadministration with strong CYP1A2 inhibitors (e.g., fluvoxamine) increases pirfenidone exposure; use with caution.,Smoking: Tobacco smoking induces CYP1A2, reducing pirfenidone exposure; advise smoking cessation.
Hypersensitivity to aminophylline or any component,Hypersensitivity to theophylline or ethylenediamine,Cardiac arrhythmias requiring immediate therapy (relative)
Severe hepatic impairment (Child-Pugh Class C),History of hypersensitivity to pirfenidone or any excipient,Coadministration with strong CYP1A2 inhibitors (e.g., fluvoxamine) due to potential toxicity
Avoid high-dose caffeine (coffee, tea, energy drinks, chocolate) as it may increase risk of side effects like nausea, anxiety, and tachycardia. Charcoal-broiled foods and a high-protein diet may increase theophylline clearance. Consistent dietary intake is recommended.
Avoid grapefruit juice (CYP3A4 interaction). Take with food to minimize GI upset. No other significant food interactions.
First trimester: Limited data; no increased risk of major malformations observed in human studies. Second and third trimesters: Risk of fetal tachycardia and jitteriness with high maternal doses; may cause transient neonatal tachycardia with chronic use. No documented teratogenicity.
Pirfenidone is classified as FDA Pregnancy Category C. In animal studies, it caused fetal toxicity (reduced fetal weight, increased skeletal variations) at doses below human exposure. There are no adequate and well-controlled studies in pregnant women. The risk of major birth defects is unknown; use only if potential benefit justifies potential risk to the fetus. First trimester: potential for teratogenicity. Second and third trimester: possible fetal toxicity from maternal exposure.
Aminophylline/theophylline is excreted into breast milk with an M/P ratio of approximately 0.6-0.7. Infant exposure is low (about 1-10% of maternal dose). Irritability and insomnia reported rarely. Use with caution, monitor infant for signs of theophylline toxicity.
It is unknown if pirfenidone is excreted in human breast milk. The M/P ratio has not been determined. Due to potential for serious adverse reactions in nursing infants, breastfeeding is not recommended during treatment and for at least 2 weeks after the last dose.
Pregnancy decreases theophylline clearance by approximately 20-30% during third trimester. Dosing adjustments may be required: monitor serum levels and adjust dose to maintain therapeutic levels. Postpartum clearance returns rapidly, requiring downward dose adjustment.
No specific dosing adjustments for pregnancy have been established. Due to changes in volume of distribution and renal clearance during pregnancy, therapeutic drug monitoring is not possible. Use lowest effective dose if absolutely necessary.
Aminophylline is a bronchodilator that releases theophylline. Monitor serum theophylline levels (therapeutic range 5-15 mcg/m L). Avoid in patients with active peptic ulcer disease, seizure disorders, or hypersensitivity to xanthines. Caution in hepatic impairment, heart failure, and elderly due to reduced clearance. Drug interactions with cimetidine, ciprofloxacin, and macrolides increase theophylline levels.
Monitor liver function tests monthly for first 6 months, then every 3 months. Avoid use in moderate to severe hepatic impairment (Child-Pugh B/C). Photosensitivity is common; advise sun avoidance and broad-spectrum sunscreen. May cause gastrointestinal issues; take with food. Dose reduction required with strong CYP1A2 inhibitors (e.g., fluvoxamine). Smoking induces CYP1A2 and reduces exposure.
Do not exceed prescribed dose. Take exactly as directed.,Avoid caffeine-containing products (coffee, tea, cola, chocolate) as they may increase side effects.,Report symptoms of toxicity: nausea, vomiting, insomnia, rapid heart rate, palpitations, or seizures.,Do not crush or chew extended-release forms; take with food if gastric upset occurs.,Do not stop abruptly without consulting your healthcare provider.
Take with food to reduce stomach upset.,Avoid sun exposure; use sunscreen and protective clothing.,Report any signs of liver problems: jaundice, dark urine, abdominal pain.,Do not smoke while taking this medication.,Avoid grapefruit juice.,Complete blood tests as scheduled.
"Concurrent administration of aminophylline, a xanthine derivative bronchodilator that is metabolized primarily by CYP1A2 and to a lesser extent CYP3A4, may reduce the clearance of ranolazine, an antianginal agent predominantly metabolized by CYP3A4 and to a lesser extent CYP2D6. Aminophylline can inhibit CYP3A4 activity, leading to increased ranolazine plasma concentrations, which elevates the risk of dose-dependent adverse effects such as QTc prolongation, dizziness, and syncope. This interaction is clinically significant and may necessitate dose adjustment or alternative therapy."
"Asunaprevir, a potent inhibitor of the drug transporter OATP1B1, can significantly decrease the serum concentration of aminophylline, a theophylline salt, likely by reducing its intestinal absorption or increasing its hepatic clearance. This interaction may lead to reduced therapeutic efficacy of aminophylline, potentially worsening respiratory symptoms in patients with asthma or COPD. Close monitoring and dose adjustment of aminophylline are recommended during coadministration with asunaprevir."
"Aminophylline, a bronchodilator, inhibits the metabolism of tibolone, a synthetic steroid hormone used for hormone replacement therapy, primarily through competitive inhibition of cytochrome P450 (CYP) 3A4 isoenzyme. This results in increased plasma concentrations of tibolone and its active metabolites, potentiating its hormonal effects and increasing the risk of adverse events such as thromboembolism, endometrial hyperplasia, or breast tenderness. Clinically, coadministration may require dose adjustments and careful monitoring for signs of estrogenic excess."
"Pirfenidone, an antifibrotic agent used for idiopathic pulmonary fibrosis, may reduce the vasodilatory efficacy of alprostadil, a prostaglandin E1 analog. This interaction likely results from pirfenidone-induced downregulation of prostaglandin receptors or modulation of cyclic AMP signaling pathways, leading to diminished smooth muscle relaxation and reduced therapeutic response to alprostadil. Consequently, patients may experience suboptimal vasodilation, potentially compromising treatment for conditions like erectile dysfunction or peripheral arterial disease."
"Pirfenidone, an antifibrotic agent, may reduce the ocular hypotensive efficacy of bimatoprost, a prostaglandin analog used for glaucoma. This interaction is postulated to occur via pirfenidone's inhibitory effects on prostaglandin synthesis or signaling pathways, potentially attenuating bimatoprost-mediated enhancement of uveoscleral outflow. Clinically, patients may experience inadequate intraocular pressure (IOP) reduction, increasing the risk of glaucoma progression."
"Pindolol, a non-selective beta-blocker with intrinsic sympathomimetic activity, may antagonize the vasodilatory effects of pirfenidone, an antifibrotic agent known to reduce systemic vascular resistance. This pharmacodynamic interaction can blunt the antihypertensive efficacy of pirfenidone, potentially leading to inadequate blood pressure control in patients with pulmonary fibrosis and concurrent hypertension. Clinically, this may necessitate dose adjustments or alternative therapies to maintain optimal cardiovascular outcomes."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% vs PIRFENIDONE, answered by our medical review team.
AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% is a Electrolyte that works by Aminophylline is a complex of theophylline and ethylenediamine, acting as a phosphodiesterase inhibitor, increasing intracellular c AMP levels; nonselective adenosine receptor antagonist; enhances cardiac inotropy, bronchodilation, and CNS stimulation.. PIRFENIDONE is a Antifibrotic Agent that works by Pirfenidone is a pyridone derivative that inhibits TGF-β1-mediated collagen synthesis, reduces fibroblast proliferation, and downregulates the production of pro-inflammatory cytokines (e.g., TNF-α, IL-1β) and growth factors. Its exact mechanism in idiopathic pulmonary fibrosis (IPF) is not fully elucidated, but it is thought to exert antifibrotic and anti-inflammatory effects.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% and PIRFENIDONE depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% is: Loading dose: 5-6 mg/kg IV over 20-30 minutes, then continuous infusion: 0.5-0.7 mg/kg/hour IV.. The standard adult dose of PIRFENIDONE is: 801 mg orally three times daily with food, total daily dose 2403 mg. Starting dose: 267 mg three times daily for first 7 days, then 534 mg three times daily for 7 days, then maintenance 801 mg three times daily.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% and PIRFENIDONE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% is classified as Category A/B. First trimester: Limited data; no increased risk of major malformations observed in human studies. Second and third trimesters: Risk of fetal tachycardia and jitteriness with high . PIRFENIDONE is classified as Category C. Pirfenidone is classified as FDA Pregnancy Category C. In animal studies, it caused fetal toxicity (reduced fetal weight, increased skeletal variations) at doses below human exposu. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.